O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
(+6.3%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18
Avg Time Held Equity + Options
2.2
years
Top 10 Avg Time Held Equity + Options
1.9
years
Top 20 Avg Time Held Equity + Options
1.8
years
Avg Time Held Equity only
2.4
years
Top 10 Avg Time Held Equity only
1.9
years
Top 20 Avg Time Held Equity only
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.63% |
| 2 | Miscellaneous | 2.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Whitehawk Therapeutics
WHWK
$169M
| $7.92M | 0.19% |
4,166,000
| – | – |
2025 Q1
2 quarters
|
|
77
Verastem
VSTM
$698M
| $7.84M | 0.18% |
+887,561
| New | +$6.61M |
2025 Q3
0 quarters
|
|
78
BrightSpring Health Services
BTSG
$12.5B
| $7.8M | 0.18% |
+263,800
| New | +$6.13M |
2025 Q3
0 quarters
|
|
79
Alumis Inc
ALMS
$784M
| $7.69M | 0.18% |
1,926,423
| – | – |
2025 Q2
1 quarter
|
|
80
BioCryst Pharmaceuticals
BCRX
$2.06B
| $6.84M | 0.16% |
+901,500
| New | +$7.51M |
2025 Q3
0 quarters
|
|
81
Milestone Pharmaceuticals
MIST
$98.1M
| $6.44M | 0.15% |
+3,221,828
| New | +$5.67M |
2025 Q3
0 quarters
|
|
82
DELISTED
Repare Therapeutics
RPTX
| $5.85M | 0.14% |
3,322,488
| – | – |
2020 Q2
21 quarters
|
|
83
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $5.66M | 0.13% |
250,000
+200,000
| +400% | +$4.66M |
2025 Q2
1 quarter
|
|
84
InspireMD
NSPR
$21.9M
| $5.14M | 0.12% |
2,133,405
| – | – |
2023 Q2
9 quarters
|
|
85
BioAge Labs
BIOA
$249M
| $4.65M | 0.11% |
790,901
-131,058
| -14% | -$614K |
2024 Q3
4 quarters
|
|
86
Jade Biosciences
JBIO
$855M
| $4.58M | 0.11% |
531,163
| – | – |
2025 Q2
1 quarter
|
|
87
Q32 Bio
QTTB
$238M
| $4.46M | 0.1% |
2,252,987
| – | – |
2024 Q1
6 quarters
|
|
|
88
CALL
BrightSpring Health Services
BTSG
$12.5B
| $4.43M | 0.1% |
+150,000
| New | +$3.49M |
2025 Q3
0 quarters
|
|
89
Definium Therapeutics
DFTX
$4.6B
| $4.34M | 0.1% |
+367,824
| New | +$3.43M |
2025 Q3
0 quarters
|
|
90
PUT
DELISTED
Crinetics Pharmaceuticals
CRNX
| $4.17M | 0.1% |
+100,000
| New | +$3.2M |
2025 Q3
0 quarters
|
|
91
Celcuity
CELC
$2.93B
| $4.15M | 0.1% |
+84,020
| New | +$3.36M |
2025 Q3
0 quarters
|
|
92
Immatics
IMTX
$1.07B
| $3.98M | 0.09% |
466,601
-253,300
| -35% | -$1.56M |
2023 Q1
10 quarters
|
|
93
CALL
Scholar Rock
SRRK
$4.82B
| $3.72M | 0.09% |
+100,000
| New | +$3.5M |
2025 Q3
0 quarters
|
|
94
CALL
TG Therapeutics
TGTX
$8.32B
| $3.61M | 0.08% |
+100,000
| New | +$3.29M |
2025 Q3
0 quarters
|
|
95
ImageneBio Inc
IMA
$47.1M
| $3.09M | 0.07% |
378,556
+83,609
| +28% | +$1.11M |
2021 Q1
18 quarters
|
|
96
Insmed
INSM
$21.4B
| $1.94M | 0.05% |
13,459
| – | – |
2024 Q4
3 quarters
|
|
97
DELISTED
AtaiBeckley Inc
ATAI
| $1.84M | 0.04% |
+347,000
| New | +$1.41M |
2025 Q3
0 quarters
|
|
98
Korro Bio
KRRO
$131M
| $1.55M | 0.04% |
32,400
| – | – |
2024 Q4
3 quarters
|
|
99
DELISTED
Mural Oncology
MURA
| $1.22M | 0.03% |
588,800
| – | – |
2025 Q2
1 quarter
|
|
100
Traws Pharma
TRAW
$6.17M
| $1.12M | 0.03% |
605,531
| – | – |
2024 Q2
5 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q3 2025 Portfolio in Review
As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.
- OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
- OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
- OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
- OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
- OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
- OrbiMed opened 24 new positions and closed 18 in Q3 2025.
- OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.
Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.